RecruitingPhase 1NCT04952272
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Enrollment
50 participants
Start Date
Mar 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- Solid advanced malignant tumors
- Age between18 and 80 years
- Life expectancy is greater than three months
Exclusion Criteria4
- Benign tumor
- Life expectancy is less than three months
- Serious medical comorbidity
- Others
Interventions
COMBINATION_PRODUCTCpG-ODN
CAR-T cells secreting scFv against OX40
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04952272
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
NCT066185991 location
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667100 locations